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Background: Ginsenosides are the major components responsible for the biochemical and pharmaco-
logical actions of ginseng, and have been shown to have various biological activities. In this study, we
investigated the antiviral activities of seven ginsenosides [protopanaxatriol (PT) type: Re, Rf, and Rg2;
protopanaxadiol (PD) type: Rb1, Rb2, Rc, and Rd)] against coxsackievirus B3 (CVB3), enterovirus 71
(EV71), and human rhinovirus 3 (HRV3).
Methods: Assays of antiviral activity and cytotoxicity were evaluated by the sulforhodamine B method
using the cytopathic effect (CPE) reduction assay.
Results: The antiviral assays demonstrated that, of the seven ginsenosides, the PT-type ginsenosides (Re,
Rf, and Rg2) possess signiﬁcant antiviral activities against CVB3 and HRV3 at a concentration of 100 mg/
mL. Among the PT-type ginsenosides, only ginsenoside Rg2 showed signiﬁcant anti-EV71 activity with no
cytotoxicity to cells at 100 mg/mL. The PD-type ginsenosides (Rb1, Rb2, Rc, and Rd), by contrast, did not
show any signiﬁcant antiviral activity against CVB3, EV71, and HRV3, and exhibited cytotoxic effects to
virus-infected cells. Notably, the antiviral efﬁcacies of PT-type ginsenosides were comparable to those of
ribavirin, a commonly used antiviral drug.
Conclusion: Collectively, our ﬁndings suggest that the ginsenosides Re, Rf, and Rg2 have the potential to
be effective in the treatment of CVB3, EV71, and HRV3 infection.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
The Picornaviridae are currently divided into nine genera,
three of which (Hepatoviruses, Rhinoviruses, and Enteroviruses) are
causative agents of human diseases [1]. Enteroviruses such as
coxsackievirus, poliovirus, and echovirus are small, nonenvelopedch Center, Korea Research Institute
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viruses are of high clinical relevance with coxsackievirus B3
(CVB3), which can cause heart-muscle infection, being an
important member. In addition, Enterovirus 71 (EV71) is a caus-
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encephalitis and poliomyelitis-like paralysis [2e5]. Human
rhinovirus (HRV) represents one of the most important etiological
agents of the common cold [6]. Although HRV-induced upper
respiratory illness is usually mild and self-limiting, there is
increasing evidence linking HRV infection to more serious med-
ical complications including asthma exacerbation [7].
To date, no effective antiviral therapies have been approved for
either the prevention or treatment of diseases caused by viruses
classiﬁed within the Picornaviridae family, including CVB3, EV71,
and HRV [8]. In this regard, many trials have been conducted to ﬁnd
antiviral components from plants. Such trials have speciﬁcally
targeted plants with intrinsic defense mechanisms in the form of
secondary metabolites against a broad range of viral infections, in
contrast to adaptive immunity induced in mammals. Indeed, me-
dicinal plants are gaining popularity as suitable alternative sources
of antiviral agents because of their multiple targets, minor side
effects, low potentials to cause resistance, and low costs [9e13].
Although several hundreds of plants with the potential to contain
novel antiviral agents have been studied, a number of potentially
useful medicinal plants still need to be evaluated and exploited for
therapeutic applications against the genetically and functionally
diverse virus families. Of these potential agents, we have focused on
ginsenosides, which are some of the major components of the
ginseng plant, Panax ginseng Meyer. The root of P. ginseng (Aral-
iaceae) is the most well-known medicinal plant in the Asian region
and is frequently used in traditional medicine [14]. Ginsenosides
are triterpenoid glycosides containing dammarane [15], and are
generally divided into two groups: the protopanaxadiol (PD) and
protopanaxatriol (PT) ginsenoside groups. The sugarmoieties in the
PD group including Rb1, Rb2, Rc, Rd, Rg3, and Rh3 are attached at
the 3-position of dammarane-type triterpenes, whereas the sugar
moieties in the PT group including Re, Rf, Rg1, Rg2, and Rh1 are
attached at the 6-position of dammarane-type triterpenes [16]. As
the major components in ginseng, ginsenosides have various bio-
logical activities such as anticancer [17], antiaging [18,19], and
antitumor activities [20]. Moreover, the antiviral activities of
ginseng against inﬂuenza virus [15], norovirus [21], and HBV [22]
have recently been reported. Although a variety of pharmacological
activities associated with seven ginsenosides (PT group: Re, Rf, and
Rg2; PD group: Rb1, Rb2, Rc, and Rd) have been demonstrated,
antiviral activities especially against CVB3, EV71 and HRV3, which
are representative viruses of the picornaviridae and have drawn a
great attention in terms of potential therapeutics, have not been
reported. Therefore, in the current study, we investigated the
antiviral activities of seven ginsenosides against CVB3, EV71, and
HRV3.
2. Materials and methods
2.1. Viruses, cell lines, and reagents
CVB3, EV71, and HRV3 were supplied by Korea Research Insti-
tute Bioscience and Biotechnology, Ochang-eup, South Korea. A
human cervix epithelial cell line (HeLa, CCL-2) and African green
monkey kidney cells (Vero, CCL-81) were purchased from the
American Type Culture Collection (Manassas, VA, USA). HeLa and
Vero cells were maintained in minimal essential medium supple-
mented with 10% fetal bovine serum and 0.01% antibioticeanti-
mycotic solution. Antibioticeantimycotic solution, trypsineEDTA,
fetal bovine serum and minimal essential medium were supplied
by Gibco BRL (Grand Island, NY, USA). Tissue culture plates were
purchased from Falcon (BD Biosciences, Franklin Lakes, NJ, USA).
Ribavirin and sulforhodamine B (SRB) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The seven ginsenosides were obtainedfrom Dr. Bae L (Elohim, Co., Daejeon, South Korea). Stock solutions
(100 mg/mL) of the antiviral compounds were dissolved in
dimethyl sulfoxide (DMSO) and were subsequently diluted in the
culture medium. The ﬁnal DMSO concentration in the culture
medium did not exceed 0.1%, which was found to have no visible
toxic effect on the cells. As a negative control, 0.1% DMSO was also
added to all no-drug control samples.
2.2. SRB assays of antiviral activity
Assays of antiviral activity and cytotoxicity were evaluated by
the SRB method using cytopathic effect (CPE) reduction recently
reported [23]. Brieﬂy, 1 day prior to infection, Vero cells were
seeded onto a 96-well culture plate at a concentration of
2  104 cells/well. The following day, the culture medium was
removed and cells were washed with phosphate-buffered saline
(PBS). The infectivity of each virus was determined by the SRB
method monitoring CPE, allowing for the percentage of cell
viability to be determined. Based on the mammalian cell viability
determined for each virus, 0.09 mL of diluted virus suspension of
CVB3 or EV71 containing CCID50 (50% cell culture infective dose) of
virus stock was added to mammalian cells. This dose was selected
to produce the appropriate CPEs 48 hours after infection. For
compound treatments, 0.01 mL of the medium containing the
selected concentration of compound was added to the cells. The
antiviral activity of each test material was determined using a 10-
fold diluted concentration range of 0.1e100 mg/mL. Four wells were
used as virus controls (virus-infected, nondrug-treated cells),
whereas four wells were used as cell controls (noninfected,
nondrug-treated cells). Culture plates were incubated at 37C in 5%
CO2 for 48 h. After washing once with PBS, 100 mL of cold (20C)
70% (v/v) acetone was added to each well and left for 30 min
at 20C. The acetone was removed from cells, after which 96-well
plates were left to dry in oven at 60C for 30 min. Then, 100 mL of
0.4% (w/v) SRB in 1% acetic acid (v/v) was added to each well and
incubated at room temperature for 30 min. Unbound SRB was
removed by washing the plates ﬁve times with 1% acetic acid (v/v),
and the plates were then left to dry in an oven. After drying for 1
day, cell morphology was assessed under a microscope at 4  10
magniﬁcation (AXIOVERT10; Zeiss, Göttingen, Deutschland) and
images were acquired. Fixed SRB in wells was solubilized with
100 mL of unbuffered Tris-base solution (10 mM), and plates were
incubated at room temperature for 30min. Absorbance in eachwell
was read at 540 nm using a VERSAmax microplate reader (Molec-
ular Devices, Palo Alto, CA, USA) and a reference absorbance of
620 nm. The antiviral activity of each test compound in CVB3- or
EV71-infected cells was calculated as a percentage of the corre-
sponding untreated control.
2.3. Cell Titer-Glo assays of antiviral activity
The antiviral activity of seven ginsenosides against HRV3 was
determined using a Cell Titer-Glo Luminescent Cell Viability Assay
kit (Promega, Madison, Wisconsin, USA). The Cell Titer-Glo Reagent
induces cell lysis and the generation of luminescence proportional
to the amount of ATP present in cells. The resulting luminescence
intensity is measured using a luminometer (Molecular Devices)
according to the manufacturer’s instructions. Brieﬂy, HeLa cells
were seeded onto a 96-well culture plate, after which 0.09 mL of
diluted HRV3 suspension containing CCID50 of the virus stock, and
0.01 mL culture medium supplemented with 20 mMMgCl2 and the
appropriate concentration of ginsenosides, was added to the cells.
The antiviral activity of each test material was determined using a
concentration series of 0.1 mg/mL, 1 mg/mL, 10 mg/mL, and 100 mg/
mL. Culture plates were incubated at 37C in 5% CO2. After 48 h,
Table 1
Cytotoxicity of Ginsenosides in Vero Cells
Ginsenosides Concentration (mg/mL)
1 10 100
PT type Re 109  1.02 109  2.53 106.9  1.03
Rf 117  1.92 121  1.63 105  3.41
Rg2 102  1.15 109  1.50 106  2.35
Ribavirin 101  2.90 105  0.13 80.7  1.22
PD type Rb1 110  0.62 117  2.16 106  0.40
Rb2 110  4.49 106  1.04 107  1.08
Rc 104  1.04 111  1.02 106  1.01
Rd 101  1.41 101  2.35 104  1.72
Ribavirin 101  1.86 105  1.22 80.7  0.13
Results are presented as the mean percentage values obtained from three inde-
pendent experiments carried out in triplicate  SD
PD, protopanaxadiol; PT, protopanaxatriol
Fig. 1. Antiviral activity of ginsenosides against CVB3 in Vero cells. Vero cells were infected with EV71, after which they were treated with the indicated concentrations (0.1e100 mg/
mL) of ginsenosides for 48 h. Ribavirin was used as a positive control for antiviral activity. Antiviral activity was investigated using a CPE reduction assay. Data are presented as
mean  SD from three independent experiments each carried out in triplicate. CPE, cytopathic effect; CVB3, coxsackievirus B3; EV71, enterovirus 71.
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plate was incubated at room temperature for 10 min. The resulting
luminescence was measured and the percentage cell viability was
calculated as described for the antiviral activity assays. Cell
morphology was assessed as described for the SRB assay.
2.4. Cytotoxicity
To measure cytotoxicity, cells were seeded onto a 96-well cul-
ture plate at a density of 2  104 cells/well. The following day, the
culture medium containing serially diluted compounds was added
to the cells and incubated for 48 h, after which the culture medium
was removed and cells were washed with PBS. The next step was
conducted as described above for the antiviral activity assay. To
calculate the CC50 values, the data were expressed as percentages
relative to controls, and CC50 values were obtained from the
resulting doseeresponse curves.
2.5. Statistical analyses
Differences across more than three groups were analyzed using
one-way analysis of variance (Graphpad PRISM, version 5.01, San
Diego, CA, USA). All results were expressed as mean  standard
deviation. Signiﬁcant differences in direct comparisons were
determined using a Tukey’s post hoc test. Differences with p < 0.05,
p < 0.01, and p < 0.001 were considered statistically signiﬁcant.
3. Results
3.1. Antiviral activity of ginsenosides against CVB3
The antiviral activities of ginsenosides against CVB3 were
assessed using the SRB method, which monitors the alteration of
CPE induced by virus infection. As a positive control, ribavirin, a
commonly used antiviral drug, was included. Of the seven ginse-
nosides tested, ginsenosides Re, Rf, and Rg2, which are classiﬁed as
PT-type ginsenosides, signiﬁcantly inhibited CVB3-induced CPE,
and increased the cell viability of Vero cells (Fig. 1). CVB3 infection
induced approximately 60% cell death in Vero cells (40% of cell
viability), and the treatment of cells with 100 mg/mL of Re, Rf, and
Rg2 increased the cell viability to 75%, 60%, and 50%, respectively.
Furthermore,10 mg/mL of ginsenosides Re and Rg2 also signiﬁcantly
reduced the CPE of CVB3 infection in Vero cells, albeit a weaker
protective effect than that of ribavirin at the same concentration. By
contrast, the PD-type ginsenosides Rb1, Rb2, Rc, and Rd did notexhibit any antiviral activity against CVB3, and 100 mg/mL of Rd, Rc,
and Rb2 even signiﬁcantly increased CVB3 infection-induced
cytotoxicity (Fig. 1).
In Vero cells treatedwith ribavirin after CVB3 infection, the drug
exhibited signiﬁcant antiviral activity at 100 mg/mL and 10 mg/mL
(Fig. 1), and the maximal efﬁcacy of ribavirin was comparable to
those of PT-type ginsenosides. Ribavirin itself was slightly toxic to
Vero cells (cell viability of approximately 81% at 100 mg/mL),
whereas none of the seven ginsenosides alone was toxic to Vero
cells at the same concentration (Table 1). Collectively, these results
suggest that ginsenosides Re, Rf, and Rg2 have signiﬁcant antiviral
activity against CVB3 without inducing cytotoxicity in Vero cells.
3.2. Antiviral activity of ginsenosides against EV71 infection
Together with coxsackievirus A16, EV71 is one of the two major
causative agents of hand, foot, and mouth disease, and thus we
sought to investigate whether ginsenosides have antiviral activity
against EV71 infection in Vero cells. Most ginsenosides assessed
using the SRB method did not have signiﬁcant antiviral activity
against EV71, and only ginsenoside Rg slightly inhibited EV71
infection-induced cytotoxicity (Fig. 2). Infection with EV71 induced
substantial cell death in Vero cells, resulting in approximately 25%
cell viability. The antiviral effect of Rg2 (10 mg/mL and 100 mg/mL) in
EV71-infected cells improved cell viability by 40%. The antiviral
effect of Rg2 was shown to be dose-dependent, and the maximal
antiviral efﬁcacy of the compound is comparable to that of
Fig. 2. Antiviral activity of ginsenosides against EV71 in Vero cells. Vero cells were infected with EV71, after which they were treated with the indicated concentrations (0.1e100 mg/
mL) of ginsenosides for 48 h. Ribavirin was used as a positive control for antiviral activity. Antiviral activity was assessed using a CPE reduction assay. Data are presented as
mean  SD from three independent experiments each carried out in triplicate. CPE, cytopathic effect; EV71, enterovirus 71.
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niﬁcant antiviral activity against EV71 infection (Fig. 2).3.3. Antiviral activity of ginsenosides against HRV3 infection
To assess the antiviral activity of ginsenosides against HRV, HeLa
cells were infected with HRV3 and treated with each of the seven
ginsenosides of interest at the indicated concentrations. HRV3
infection itself induced cell death in HeLa cells and resulted in 50%
cell viability (Fig. 3). Similar to the antiviral effect against CVB3, two
PT-type ginsenosides (Rf and Rg2) signiﬁcantly increased cell
viability to 80% (Fig. 3) as shown using the luminescent cell viability
assay described in the “Materials and methods” section. The gin-
senoside Re, however, had little protective effect in HRV3-infected
HeLa cells. Furthermore, none of the PD-type ginsenosides (Rd, Rc,
Rb1, and Rb2) had a protective on cell viability, but instead the
compounds (100 mg/mL) signiﬁcantly increased HRV3 infection-
induced cell death in HeLa cells (Fig. 3), despite not inducing
cytotoxicity in uninfected HeLa cells (Table 1). Collectively, these
results suggest that the PT-type ginsenosides Rf and Rg2 have
antiviral activity against HRV3.Fig. 3. Antiviral activity of ginsenosides against HRV3 in HeLa cells. HeLa cells were infe
ginsenosides for 48 h. Antiviral activity was assessed using a Cell Titer-Glo Luminescent cell
each carried out in triplicate. HRV3, human rhinovirus 3.3.4. Effect of ginsenosides on CVB3- and HRV3-induced cytotoxicity
In order to examine the potential morphological alteration of
Vero cells by ginsenosides, cells were treated with the compounds
for 48 h and assessed by microscopy. In the absence of infection
with CVB3, cells treated with DMSO or 100 mg/mL ginsenosides
showed no obvious signs of cytotoxicity, exhibiting the typical
spread-out shape associated with the normal morphology of Vero
cells (Fig. 4). Infection of Vero cells with CVB3 resulted in a severe
CPE, whereas CVB3-infected Vero cells treated with ginsenosides
Re, Rf, and Rg2, exhibited noticeably reduced CPE compared with
untreated CVB3-infected cells. Treatment of CVB3-infected Vero
cells with ribavirin signiﬁcantly reduced CPE. These results indicate
that the CPE of CVB3 infection is prevented by ginsenosides Re, Rf,
and Rg2.
The viability of HeLa cells following HRV3 infection was also
monitored. In the absence of HRV3 infection, the treatment of
HeLa cells with ginsenosides for 48 h altered neither the viability
nor the morphology of the cells compared with vehicle-treated
cells (Fig. 5). HRV3 infection reduced the viability of cells, and as
assessed using the SRB assay, ribavirin was found to signiﬁcantly
inhibit HRV3 infection-induced cell death. Likewise, ginsenosidescted with HRV3, after which they were treated with the indicated concentrations of
viability assay. Data are presented as mean  SD from three independent experiments
Fig. 4. Morphological assessment of coxsackievirus B3 (CVB3)-infected Vero cells following ginsenoside treatment. CVB3-infected and uninfected Vero cells were treated with
either ribavirin or 100 mg/mL ginsenosides. After staining of viable cells with sulforhodamine B (SRB), cell morphology was assessed by microscopy. (A) Untreated, uninfected cells;
(BeI) uninfected cells treated with ginsenosides (B) Rb1, (C) Rb2, (D) Rd, (E) Rc, (F) Re, (G) Rf, and (H) Rg2; and with ribavirin; (J) untreated CVB3-infected cells; (KeR) CVB3-infected
cells treated with ginsenosides (K) Rb1, (L) Rb2, (M) Rd, (N) Rc, (O) Re, (P) Rf, (Q) Rg2; and with (R) ribavirin.
J.-H. Song et al / Antiviral activity of ginsenosides 177Re, Rf, and Rg2 reduced HRV3 infection-induced cell death,
whereas ginsenosides Rd, Rc, and Rb2 induced severe cytotoxicity
in HeLa cells infected with HRV3. The CPE of HRV3 infection is
thus prevented by treatment with ginsenosides Re, Rf, and Rg2.
4. Discussion
P. ginseng is a traditional medicine that has been used in Korea
and China for more than 5000 years [24]. Steaming and
fermentation of skinned ginseng resulted in red ginseng having a
somewhat different chemical composition compared with the
original ginseng. Many saponins including ginsenosides found in
ginseng and red ginseng have been shown to have various
beneﬁcial effects including adjuvant properties and antiviral ac-
tivity. Some ginsenosides elicited adjuvant effects when used in
combination with several vaccines including inﬂuenza and
porcine parvovirus vaccines [15,25]. Ginsenosides Rg1, Rg2, Rg3,
Rb1, and Re, in particular, exhibit potent adjuvant activity, and
ginsenoside Re increased the immune response against an inac-
tivated H3N2 inﬂuenza vaccine [15]. Furthermore, the oralFig. 5. Morphological assessment of human rhinovirus 3 (HRV3)-infected Hela cells followin
either ribavirin or 100 mg/mL ginsenoside. After staining of viable cells with sulforhodamine
(BeI) uninfected cells treated with ginsenosides (B) Rb1, (C) Rb2, (D) Rd, (E) Rc, (F) Re, (G) Rf,
cells treated with ginsenosides (K) Rb1, (L) Rb2, (M) Rd, (N) Rc, (O) Re, (P) Rf, (Q) Rg2; andadministration of ginsenoside Rb2 prior to infection of mice with
hemagglutinating virus of Japan protected the infected mice from
severe acute lung infection. This effect was shown to be due to
antiviral activity of Rb2 as well as an enhancement of mucosal
immunity by the compound [26]. Interestingly, a recent study
showed that ginsenosides Rg1 and Rb1, as well as red ginseng
extract, exhibited antiviral activity against hepatitis A virus,
which is classiﬁed in the Picornaviridae family together with
Enteroviruses [27]. However, there have been no previous reports
on the antiviral activity of ginsenosides against other viruses
included in Picornaviridae. In the current study, we show that
ginsenosides Re, Rf, and Rg2 have signiﬁcant antiviral activity
against CVB3 and HRV3 infection, and thus, considering their
potential adjuvanticity, these compounds may be effective in
eliminating CVB3 and HRV3 in infected hosts.
It is believed that CVB3 is an etiological agent causing
myocarditis and dilated cardiomyopathy, and outbreaks of CVB3
infection occur worldwide annually [28]. Currently, there are no
effective therapeutic agents against CVB3, and only ribavirin has
been shown to have weak antiviral activity against CVB3 infectiong ginsenosides treatment. HRV3-infected and uninfected HeLa cells were treated with
B (SRB), cell morphology was assessed by microscopy. (A) Untreated, uninfected cells;
(H) Rg2; and with (I) ribavirin; (J) untreated HRV3-infected cells; (KdR) HRV3-infected
with (R) ribavirin.
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of HRV infection, and most associated treatments function only to
reduce the symptoms of the infection. Because of the challenges
associated with the development of appropriate vaccines as a
means of controlling rhinovirus infection, mainly due to the ge-
netic variability of rhinoviruses, most research efforts toward
combating rhinovirus infection have been focused on the devel-
opment of effective antiviral drugs. A great variety of compounds
and compound classes have been shown to exhibit antirhinovirus
activity in vitro, but few have been found to be effective at the
clinical level. The antiviral activities of whole extracts produced
from Uncaria tomentosa, Guettarda platypoda [32], rhizome of
Tamus communis [33], Calendula arvensis [34], root of Allium sat-
ivum [35], Zingiber ofﬁcinale [36], and Eleutherococcus senticosus
[37] have been reported; however, antiviral activities of ginse-
nosides and even of ginseng against HRV have not yet been
reported.
Pleconaril is an orally administrable small-molecule inhibitor of
human picornavirus replication. The compound is known to be
integrated into a hydrophobic pocket within the major coat protein
of viruses including human Picornaviridae, and to inhibit the cor-
rect functioning of this protein. Consequently, pleconaril inhibits
the attachment of some viruses to their cellular receptors and
blocks the viral uncoating process [38,39]. Recently, however, the
US Food and Drug Administration did not approve pleconaril for
clinical use owing to concerns of emergence of viral resistance and
side effects in patients [40]. Ribavirin has also been used in at-
tempts to treat various DNA and RNA virus infections, although
acquired resistance to the drug has been demonstrated in various
virus populations and in some patients [29]. The development of
antiviral drugs targeting viruses classiﬁed in the Picornaviridae
family is therefore urgently required. In the current study, the
antiviral activities of ginsenosides against CVB3, EV71, and HRV3
have been evaluated and compared with the currently used anti-
viral drug ribavirin, which exhibits some antiviral activity. The re-
sults of our study demonstrating the antiviral activities of
ginsenosides suggest that the compounds may provide a thera-
peutic option for the treatment of CVB3, EV71, and HRV3 infection;
furthermore, the compounds could potentially be effective against
Picornaviridae viruses in general.
Strong anti-CVB3 and anti-HRV3 activity was demonstrated for
PT-type ginsenosides (Re, Rf, and Rg2), and ginsenoside Rg2 of the
PT type showed anti-EV71 activity, despite its relatively weak ac-
tivity. By contrast, PD-type ginsenosides (Rb1, Rb2, Rc, and Rd) did
not show any antiviral activity against CVB3, EV71 and HRV3, and
even increased the cytotoxicity induced by virus infection. Taken
together, these results indicate that the antiviral activities of gin-
senosides against CVB3, EV71, and HRV3 appear to be selectively
dependent on the type of ginsenosides. Ginsenoside is divided into
PD saponin and PT saponin by its chemical structure. The other
study group investigated and compared the antiobesity activity of
PD-type and PT-type saponins in rats fed a high fat diet. In
conclusion, PD- and PT-type saponins have been shown to exert
antiobesity effects in the rats fed with a high fat diet by reducing
their body weight, their food consumption, and their fat storage.
However, PD-type saponins have more potent antiobesity proper-
ties than PT-type saponins [41].We think our data also demonstrate
that antiviral activities are related to the chemical structures.
Therefore, further studies are required to explore the detailed
antiviral mechanisms of ginsenosides of the PT type as well as to
assess in vivo antiviral activity.
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